share_log

上海莱士(002252.SZ):目前正在开展I期临床研究的SR604是利用生物合成技术生产的重组蛋白质单克隆抗体产品

Shanghai Laishi (002252.SZ): SR604, which is currently undergoing phase I clinical research, is a recombinant protein monoclonal antibody product produced using biosynthesis technology

Gelonghui Finance ·  May 14 04:07

Glonghui May 14 丨 Shanghai Rice (002252.SZ) held a performance briefing on May 13, 2024, to discuss “Does the company have synthetic organisms?” The company replied that SR604, which the company is currently carrying out phase I clinical research, is a recombinant protein monoclonal antibody product produced using biosynthesis technology.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment